Unknown

Dataset Information

0

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.


ABSTRACT: Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, TP53 un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus rituximab. The regimen was completed in all the patients with acceptable toxicity. All patients achieved a complete clinical response with no evidence of residual disease at bone marrow biopsy and flow-cytometry examination. After a median follow-up of 19 months, the 3 subjects are still in complete remission. In this work, bendamustine plus rituximab proved to be an effective and feasible first-line treatment strategy for elderly patients with TP53 un-mutated HCLv.

SUBMITTER: Visentin A 

PROVIDER: S-EPMC5746417 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors. HCLv is characterized by unfavorable prognosis, low complete remission rates and limited disease control following classical hairy cell leukemia-based regimens. In this study, we report 3 cases of elderly patients with treatment-naive, <i>TP53</i> un-mutated HCLv, who were effectively treated with four cycles of bendamustine plus ritux  ...[more]

Similar Datasets

| S-EPMC3861900 | biostudies-literature
| S-EPMC3867590 | biostudies-literature
| S-EPMC5865431 | biostudies-literature
| S-EPMC8320332 | biostudies-literature
| S-EPMC7213585 | biostudies-literature
| S-EPMC9153043 | biostudies-literature
| S-EPMC10982641 | biostudies-literature
| S-EPMC7735159 | biostudies-literature
| S-EPMC8346601 | biostudies-literature
| S-EPMC10182158 | biostudies-literature